Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma was incorporated in 2013 and is based in London, United Kingdom with operations in the US and EU. It is listed on the AIM market of the London Stock Exchange under the ticker code VRP.
To develop and commercialise best-in-class treatments for chronic and acute respiratory diseases that are currently inadequately served by existing therapies.
To be recognised as a trusted and innovative global leader in respiratory disease treatments.
More Contents:
